Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lithoren
- Development stage
- Unknown
- Lead developer
- Meditrina Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lithoren is a specialized dietary supplement, classified as a Food for Special Medical Purposes (FSMP), developed by MEDITRINA for the management and prevention of kidney stones (urolithiasis). Its formulation combines potassium citrate, magnesium citrate, and vitamin B6 (pyridoxine hydrochloride). Lithoren acts as a urine alkalizer, causing a dose-dependent increase in urinary pH and citrate levels. This biochemical shift inhibits the crystallization, aggregation, and formation of calcium oxalate and phosphate complexes, which are the primary constituents of most renal calculi. It is clinically used to prevent stone recurrence and to improve outcomes following lithotripsy procedures.
- Brand names
- Lithoren
02
Targets
SPT (Serine palmitoyltransferase)Hydroxyapatite
Beyond the preview
Go deeper on Lithoren.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lithoren.